The global antacids tablets market is expected to grow at a significant CAGR during the forecast period (2022-2028). Antacids are over-the-counter medications that are used to relieve heartburn, stomach pain, acid reflux, and stomach distress. It protects the stomach, duodenum, and esophagus from harsh acids created during food digestion. The availability of a variety of chewable tablets in a number of tastes that aid in patient adherence to medication is projected to drive global antacid tablet market growth. As the tablets are the low-cost oral dose form and are easy to handle, use, and carry, they are the most extensively utilized solid dosage form. 

Furthermore, the market is predicted to rise due to the growing geriatric population, which is more susceptible to gastrointestinal problems. Acidic problems are common in the older population, making it a unique challenge for both the primary care physician and the gastroenterologist. Furthermore, such patients are more likely to have a number of symptomatic illnesses, such as erosive esophagitis, Barrett's esophagus, and esophageal cancer, which require a combination of medications to cure, and the usage of antacids is substantially higher in these cases. According to the 2019 revision of the World Population Prospects, by 2050, one in every six people in the world will be over the age of 65 (16%), up from one in every eleven people in 2019.

The key companies operating in the global antacid tablet market are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, in January 2019, Dr. Reddy's laboratories introduced generic omeprazole delayed-release tablets for the treatment of heartburn in the US. In April 2018, Perrigo also released a new orally disintegrating omeprazole tablet for the treatment of persistent heartburn. In October 2020, Dr. Reddy's laboratories re-launched Famotidine Tablets USP, 10 mg and 20 mg, over-the-counter (OTC) in the US market. In March 2020, Lupin released an authorized generic for Horizon Therapeutics PLC's Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets in the US. The drug is a mixture of naproxen and esomeprazole magnesium, with naproxen being used for symptomatic treatment of arthritis and esomeprazole magnesium being used to reduce the risk of naproxen-associated stomach ulcers. 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Distribution Channel 

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Johnson and Johnson Services, Inc., GlaxoSmithKline plc, and Sanofi S.A., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antacids Tablets Market Report by Segment

By Distribution Channel 

• Online
• Offline

Global Antacids Tablets Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa 
•